Trial Profile

Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent GVHD After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Basiliximab (Primary) ; Ciclosporin
Indications Graft-versus-host disease
Focus Therapeutic Use

Most Recent Events

19 Nov 2019 Results (n=14 ) assessing Pharmacokinetics of Basiliximab for the prevention of GVHD published in the Pharmacotherapy
26 Oct 2012 Planned end date changed from 1 Sep 2013 to 1 Oct 2014 as reported by ClinicalTrials.gov.
15 May 2012 Actual patient number 17 added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com